Mylan launches generic version of Glaxo's Avodart in the U.S.

• Mylan N.V.'s (MYL -5%) U.S. launch of its generic version of GlaxoSmithKline's (GSK -3.4%) prostate drug Avodart (dutasteride) is underway. According to IMS, the U.S. market is ~$300M.
• Dutasteride is indicated for the treatment of men with symptomatic benign prostate hyperplasia (enlarged prostate).